245 related articles for article (PubMed ID: 15988911)
1. Vaccine therapy for non-Hodgkin's lymphoma and other B-cell malignancies.
Leitch HA; Connors JM
Curr Opin Investig Drugs; 2005 Jun; 6(6):597-604. PubMed ID: 15988911
[TBL] [Abstract][Full Text] [Related]
2. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.
Ruffini PA; Neelapu SS; Kwak LW; Biragyn A
Haematologica; 2002 Sep; 87(9):989-1001. PubMed ID: 12217812
[TBL] [Abstract][Full Text] [Related]
3. The role of idiotype vaccines in the treatment of human B-cell malignancies.
Bendandi M
Expert Rev Vaccines; 2004 Apr; 3(2):163-70. PubMed ID: 15056042
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapeutic strategies for the treatment of plasma cell malignancies.
Treon SP; Raje N; Anderson KC
Semin Oncol; 2000 Oct; 27(5):598-613. PubMed ID: 11049026
[TBL] [Abstract][Full Text] [Related]
5. Active immunotherapy of multiple myeloma.
Houet L; Veelken H
Eur J Cancer; 2006 Jul; 42(11):1653-60. PubMed ID: 16797966
[TBL] [Abstract][Full Text] [Related]
6. Phase I trial of a novel intradermal idiotype vaccine in patients with advanced B-cell lymphoma: specific immune responses despite profound immunosuppression.
Bertinetti C; Zirlik K; Heining-Mikesch K; Ihorst G; Dierbach H; Waller CF; Veelken H
Cancer Res; 2006 Apr; 66(8):4496-502. PubMed ID: 16618777
[TBL] [Abstract][Full Text] [Related]
7. Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype.
Weng WK; Czerwinski D; Timmerman J; Hsu FJ; Levy R
J Clin Oncol; 2004 Dec; 22(23):4717-24. PubMed ID: 15483014
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic lymphoma vaccines: importance of T-cell immunity.
Neelapu SS; Lee ST; Qin H; Cha SC; Woo AF; Kwak LW
Expert Rev Vaccines; 2006 Jun; 5(3):381-94. PubMed ID: 16827622
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy for non-Hodgkin's lymphoma: monoclonal antibodies and vaccines.
Maloney DG
J Clin Oncol; 2005 Sep; 23(26):6421-8. PubMed ID: 16155029
[TBL] [Abstract][Full Text] [Related]
10. Idiotypic vaccination in B-cell malignancies.
Bianchi A; Massaia M
Mol Med Today; 1997 Oct; 3(10):435-41. PubMed ID: 9358470
[TBL] [Abstract][Full Text] [Related]
11. Anti-Gal-mediated targeting of human B lymphoma cells to antigen-presenting cells: a potential method for immunotherapy using autologous tumor cells.
Manches O; Plumas J; Lui G; Chaperot L; Molens JP; Sotto JJ; Bensa JC; Galili U
Haematologica; 2005 May; 90(5):625-34. PubMed ID: 15921377
[TBL] [Abstract][Full Text] [Related]
12. Personalized immunotherapy for the treatment of non-Hodgkin lymphoma: a promising approach.
Vose J
Clin Adv Hematol Oncol; 2005 Dec; 3(12):923-32. PubMed ID: 16555434
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy of hematological malignancies using dendritic cells.
Van de Velde AL; Berneman ZN; Van Tendeloo VF
Bull Cancer; 2008 Mar; 95(3):320-6. PubMed ID: 18390412
[TBL] [Abstract][Full Text] [Related]
14. Accomplishments and perspectives of immunological interventions in lymphoproliferative disorders.
Milosević DB
J Exp Clin Cancer Res; 2004 Mar; 23(1):9-13. PubMed ID: 15149145
[TBL] [Abstract][Full Text] [Related]
15. Anti-idiotypic vaccination in the treatment of low-grade B-cell lymphoma.
Barrios Y; Cabrera R; Yáñez R; Briz M; Plaza A; Forés R; Fernández MN; Díaz-Espada F
Haematologica; 2002 Apr; 87(4):400-7. PubMed ID: 11940484
[TBL] [Abstract][Full Text] [Related]
16. Effect of linkage of transduction domain sequences to a lymphoma idiotype DNA vaccine on vaccine effectiveness.
Ashour AK; Petersen JL; McIlhaney MM; Vose JM; Solheim JC
Hybridoma (Larchmt); 2006 Oct; 25(5):306-8. PubMed ID: 17044787
[TBL] [Abstract][Full Text] [Related]
17. Activated T-cell-mediated immunotherapy with a chimeric receptor against CD38 in B-cell non-Hodgkin lymphoma.
Mihara K; Yanagihara K; Takigahira M; Imai C; Kitanaka A; Takihara Y; Kimura A
J Immunother; 2009 Sep; 32(7):737-43. PubMed ID: 19561535
[TBL] [Abstract][Full Text] [Related]
18. DNA vaccines against haematological malignancies.
Stevenson FK; King CA; Spellerberg MB; Zhu D; Rice J; Sahota S; Thompsett A; Radl J; Hamblin TJ
Haematologica; 1999 Jun; 84 Suppl EHA-4():11-3. PubMed ID: 10907456
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy in multiple myeloma: current strategies and future prospects.
Yi Q
Expert Rev Vaccines; 2003 Jun; 2(3):391-8. PubMed ID: 12903804
[TBL] [Abstract][Full Text] [Related]
20. DNA vaccines with single-chain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma.
King CA; Spellerberg MB; Zhu D; Rice J; Sahota SS; Thompsett AR; Hamblin TJ; Radl J; Stevenson FK
Nat Med; 1998 Nov; 4(11):1281-6. PubMed ID: 9809552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
